Pulmonx Corporation Common Stock (LUNG)
Stock · NASDAQ · Health Care
$1.77as of 10/16/2026
Price chart
Active signals
LUNG Signal Track Record
How signals performed across all stocks →What LUNG's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -1.2% | 46% | July 30, 2026 |
| Bollinger Band Breakout | 23 | -12.1% | 35% | August 3, 2026 |
| Bollinger Band Breakdown | 16 | -6.9% | 25% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -4.8% | 30% | July 30, 2026 |
| Any 20-session window (baseline) | -1.5% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LUNG
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 296
- Website
- pulmonx.com/
Fundamentals
- 1-day range
- $1.82$1.88
- Market cap
- $88.04M
- P/E (trailing)
- —
- P/E (forward)
- -1.95
- EPS (trailing)
- $-1.16
- Dividend yield
- —
- Beta
- 0.27
- Avg. volume
- 488.6K
How Pulmonx Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Pulmonx Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- LUNGPulmonx Corporation Common Stock$1.78▼ 3.78%Market cap $88.04MP/E —$1.13$2.89
- PYPDPolyPid Ltd. Ordinary Shares$4.72▼ 3.67%Market cap $91.79MP/E —$3.1$5.73
- SKINSkinHealth Systems Inc. Class A Common Stock$10.56▼ 16.19%Market cap $99.91MP/E —$10.01$34.8
- LNSRLENSAR Inc. Common Stock$5.8▼ 3.81%Market cap $70.43MP/E 2.15$4.95$12.94
- GUTSFractyl Health Inc. Common Stock$1.55▼ 62.74%Market cap $108.99MP/E —$3.78$29.34
- XTNTXtant Medical Holdings Inc. Common Stock$0.29▼ 3.33%Market cap $62.09MP/E 23.84$0.2702$0.95
- DXRDaxor Corporation Common Stock$10.05▼ 1.47%Market cap $61.18MP/E 10.12$8.56$14.76
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LUNG Pulmonx Corporation Common Stock | $88.04M | — | $1.78 | ▼ 3.78% | $1.13$2.89 |
| PYPD PolyPid Ltd. Ordinary Shares | $91.79M | — | $4.72 | ▼ 3.67% | $3.1$5.73 |
| SKIN SkinHealth Systems Inc. Class A Common Stock | $99.91M | — | $10.56 | ▼ 16.19% | $10.01$34.8 |
| LNSR LENSAR Inc. Common Stock | $70.43M | 2.15 | $5.8 | ▼ 3.81% | $4.95$12.94 |
| GUTS Fractyl Health Inc. Common Stock | $108.99M | — | $1.55 | ▼ 62.74% | $3.78$29.34 |
| XTNT Xtant Medical Holdings Inc. Common Stock | $62.09M | 23.84 | $0.29 | ▼ 3.33% | $0.2702$0.95 |
| DXR Daxor Corporation Common Stock | $61.18M | 10.12 | $10.05 | ▼ 1.47% | $8.56$14.76 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Sullivan Tiffany · June 5, 2026 · Grant40.0K
- Melenikiotou Georgia · June 5, 2026 · Grant40.0K
- Thomas William Burns · June 5, 2026 · Grant40.0K
- Florin Daniel P · June 5, 2026 · Grant40.0K
- Dana G. Mead Jr. · June 5, 2026 · Grant40.0K
- Richard Ferrari · June 5, 2026 · Grant40.0K
- French Glendon E. III · June 2, 2026 · Sale13.5K @ $1.57
- Radhakrishnan Srikanth · June 1, 2026 · Sale6.0K @ $1.54
- Radhakrishnan Srikanth · June 1, 2026 · Sale3.7K @ $1.54
- Radhakrishnan Srikanth · June 1, 2026 · Sale2.2K @ $1.54
- Radhakrishnan Srikanth · June 1, 2026 · Sale2.7K @ $1.54
- French Glendon E. III · June 1, 2026 · Sale38.5K @ $1.54
- French Glendon E. III · June 1, 2026 · Sale4.2K @ $1.54
- Rose Geoffrey Beran · June 1, 2026 · Sale2.3K @ $1.54
- Rose Geoffrey Beran · June 1, 2026 · Sale2.4K @ $1.54
Institutional Ownership
March 31, 2026
- Total shares held
- 28.63M
- Total value held
- $36.45M
- Institutional holders
- 108
- Unknown4.72M
- Unknown3.99M
- Unknown2.79M
- Unknown2.66M
- Unknown1.63M
- Unknown1.17M
- Unknown1.16M
- Unknown944.5K
- Unknown809.1K
- Unknown768.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Pulmonx Sets Q3 2026 Earnings Date for October 27
Pulmonx Corporation has announced that it will report its third-quarter 2026 financial results on October 27, 2026. This scheduled update provides a specific timeline for investors to review the company's latest performance metrics. The announcement serves as a standard corporate disclosure rather than a change in business operations.
Pulmonx Sets Q3 2026 Earnings Date for October 27. Pulmonx Corporation has announced that it will report its third-quarter 2026 financial results on October 27, 2026. This scheduled update provides a specific timeline for investors to review the company's latest performance metrics. The announcement serves as a standard corporate disclosure rather than a change in business operations.